In vivo efficacy of anti-glycoprotein 41, but not anti-glycoprotein 120, immunotoxins in a mouse model of HIV infection

Journal of Immunology

Volumn 170, Issue 4, 2003, Pages 2236-2241

  Pincus, Seth H ^a,b,f   Fang, Hua ^a,e   Wilkinson, Royce A ^a   Marcotte, Tamera K ^a   Robinson, James E ^c   Olson, William C ^d  

^a MONTANA STATE UNIVERSITY   (United States)

^b LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d A Subsidiary of Lantheus Holdings   (United States)

^e BRISTOL MYERS SQUIBB   (United States)

^f The Research Institute for Children at Children's Hospital New Orleans   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOTOXIN; MONOCLONAL ANTIBODY; PSEUDOMONAS EXOTOXIN;

ANIMAL CELL; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS INFECTION;

EID: 0037442143     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.170.4.2236     Document Type: Article

References (43)

1. Bell, K. D., O. Ramilo, and E. S. Vitetta. 1993. Combined use of an immunotoxin and cyclosporine to prevent both activated and quiescent peripheral blood T cells from producing type I human immunodeficiency virus. Proc. Natl. Acad. Sci. USA 90:1411.
2. McCoig, C., G. Van Dyke, C.-S. Chou, L. J. Picker, O. Ramilo, and E. S. Vitetta. 1999. An anti-CD45RO immunotoxin eliminates T cells latently infected with HIV-1 in vitro. Proc. Natl. Acad. Sci. USA 96:11482.
3. Uckun, F. M., K. Bellomy, K. O'Neill, Y. Messinger, T. Johnson, and C.-L. Chen. 1999. Toxicity. biological activity, and pharmacokinetics of TXU (anti-CD7)-pokeweed antiviral protein in chimpanzees and adult patients infected with HIV-1. J. Pharmacol. Exp. Ther. 291:1301.
4. Berger, E. A., K. A. Clouse, V. K. Chaudhary, S. Chakrabarti, D. J. FitzGerald, I. Pastan, and B. Moss. 1989. CD4-Pseudomonas exotoxin hybrid protein blocks the spread of human immunodeficiency virus infection in vitro and is active against cells expressing the envelope glycoproteins from diverse primate immunodeficiency retroviruses. Proc. Natl. Acad. Sci. USA 86:9539.
5. Till, M. A., V. Ghetie, T. Gregory, E. J. Patzer, J. P. Porter, J. W. Uhr, D. J. Capon, and E. S. Vitetta. 1988. HIV-infected cells are killed by rCD4-ricin A chain. Science 242:1166.
6. Chaudhary, V. K., T. Mizukami, T. R. Fuerst, D. J. FitzGerald, B. Moss, I. Pastan, and E. A. Berger. 1988. Selective killing of HIV-infected cells by recombinant human CD4-Pseudomonas exotoxin hybrid protein. Nature 335:369.
7. Till, M. A., S. Zolla-Pazner, M. K. Gorny, J. S. Patton, J. W. Uhr, and E. S. Vitetta. 1989. Human immunodeficiency virus-infected T cells and monocytes are killed by monoclonal human anti-gp41 antibodies coupled to ricin A chain. Proc. Natl. Acad. Sci. USA 86:1987.
8. Pincus, S. H., K. Wehrly, and B. Chesebro. 1989. Treatment of HIV tissue culture infection with monoclonal antibody-ricin A chain conjugates. J. Immunol. 142:3070.
9. Pincus, S. H., R. L. Cole, E. M. Hersh, D. Lake, Y. Masuho, P. J. Durda, and J. McClure. 1991. In vitro efficacy of anti-HIV immunotoxins targeted by various antibodies to the envelope protein. J. Immunol. 146:4315.
10. Pincus, S. H., K. Wehrly, R. Cole, H. Fang, G. K. Lewis, J. McClure, A. J. Conley, B. Wahren, M. R. Posner, A. L. Notkins, et al. 1996. In vitro effects of anti-HIV immunotoxins directed against multiple epitopes on the HIV-1 envelope glycoprotein gp160. AIDS Res. Hum. Retroviruses 12:1041.
11. Ashorn, P., B. Moss, J. N. Weinstein, V. K. Chaudhary, D. J. FitzGerald, I. Pastan, and E. A. Berger. 1990. Elimination of infectious human immunodeficiency virus from human T-cell cultures by synergistic action of CD4-Pseudomonas exotoxin and reverse transcriptase inhibitors. Proc. Natl. Acad. Sci. USA 87:8889.
12. Pincus, S. H., and J. McClure. 1993. Soluble CD4 enhances the efficacy of immunotoxins directed against gp41 of the human immunodeficiency virus. Proc. Natl. Acad. Sci. USA 90:332.
13. Ashorn, P., G. Englund, M. A. Martin, B. Moss, and E. A. Berger. 1991. Anti-HIV activity of CD4-Pseudomonas exotoxin on infected primary human lymphocytes and monocyte/macrophages. J. Infect. Dis. 163:703.
14. Ashorn, P., B. Moss, and E. A. Berger. 1992. Activity of CD4-Pseudomonas exotoxin against cells expressing diverse forms of the HIV and SIV envelope glycoproteins. J. Acquired Immune Defic. Syndr. 5:70.
15. Davey, R. T., C. M. Boenning, B. R. Herpin, D. H. Batts, J. A. Metcalf, L. Wathen, S. R. Cox, M. A. Polis, J. A. Kovacs, J. Falloon, et al. 1994. Recombinant soluble CD4-Pseudomonas exotoxin, a novel immunotoxin, in the treatment of individuals infected with HIV. J. Infect. Dis. 170:1180.
16. Ramachandran, R. V., D. A. Katzenstein, R. Wood, D. H. Batts, and T. C. Merigan. 1994. Failure of short-term CD4-PE40 infusions to reduce viral load in HIV infected individuals. J. Infect. Dis. 170:1009.
17. Pincus, S. H. 1996. Therapeutic potential of anti-HIV immunotoxins. Antiviral Res. 33:1.
18. Pincus, S. H. 2000. Targeting drugs to HIV-infected cells. In Drug Targeting, Vol. 25. G. E. Francis, ed. Humana Press, Totowa, NJ, p. 193.
19. Allaway, G. P., K. L. Davis-Bruno, G. A. Beaudry, E. B. Garcia, E. L. Wong, A. M. Ryder, K. W. Hasel, M.-C. Gauduin, R. A. Koup, S. McDougal, and P. J. Maddon. 1995. Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV-1 isolates. AIDS Res. Hum. Retroviruses 11:533.
20. Jacobson, J. M., I. Lowy, C. V. Fletcher, T. J. O'Neill, D. N. Tran, T. J. Ketas, A. Trkola, M. E. Klotman, P. J. Maddon, W. C. Olson, and R. J. Israel. 2000. Single-dose safety, pharmacology, and antiviral activity of HIV type 1 entry inhibitor PRO 542 in HIV-infected adults. J. Infect. Dis. 182:326.
21. Shearer, W. T., R. J. Israel, S. Starr, C. V. Fletcher, D. Wara, M. Rathore, J. Church, J. DeVille, T. Fenton, B. Graham, et al. 2000. Recombinant CD4-IgG2 in human immunodeficiency virus type 1-infected children: phase 1/2 study. J. Infect. Dis. 182:1774.
22. + cell line H9. AIDS Res. Hum. Retroviruses 5:253.
23. Adachi, A., H. E. Gendelman, S. Koenig, T. Folks, R. Willey, A. Rabson, and M. A. Martin. 1986. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 59:284.
24. Pincus, S. H., and K. Wehrly. 1990. AZT demonstrates anti-HIV-1 activity in persistently infected cell lines: implications for combination chemotherapy and immunotherapy. J. Infect. Dis. 162:1233.
25. + T-cell clone (PMI): failure to down-regulate CD4 and to interfere with cell-line-tropic HIV-1. J. Virol. 69:3712.
26. Chesebro, B., K. Wehrly, J. Nishio, and S. Perryman. 1992. Macrophage-tropic HIV isolates from different patients exhibit unusual V3 envelope sequence homogeneity in comparison with T-cell-tropic isolates: definition of critical amino acids involved in cell tropism. J. Virol. 66:6547.
27. Platt, E. J., K. Wehrly, S. R. Kuhmann, B. Chesebro, and D. Kabat. 1998. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophage-tropic isolates of HIV-1. J. Virol. 72:2855.
28. Pincus, S. H., T. K. Marcotte, B. M. Forsyth, and H. Fang. 2001. In vivo testing of anti-HIV immunotoxins. In Immunotoxin Methods and Protocols, Vol. 166. W. A. Hall, ed. Humana Press, Totowa, NJ, p. 277.
29. Jacobson, J. M., N. Colman, N. A. Ostrow, R. W. Simson, D. Tomesch, L. Marlin, M. Rao, J. L. Mills, J. Clemens, and A. M. Prince. 1993. Passive immunotherapy in the treatment of advanced human immunodeficiency virus infection. J. Infect. Dis. 168:298.
30. Shultz, L. D., P. A. Schweitzer, S. W. Christianson, B. Gott, I. B. Schweitzer, B. Tennent, S. McKenna, L. Mobraaten, T. V. Rajan, D. L. Greiner, and E. H. Leiter. 1995. Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. J. Immunol. 154:180.
31. McCallus, D., K. Ugen, A. Sato, W. Milliams, and D. Weiner. 1992. Construction of a recombinant bacterial human CD4 expression system producing a bioactive CD4 molecule. Viral Immunol. 5:163.
32. Ogata, M., I. Pastan, and D. FitzGerald. 1991. Analysis of Pseudomonas exotoxin activation and conformational changes by using monoclonal antibodies as probes. Infect. Immun. 59:407.
33. LeMaistre, C. F., S. Rosen, A. Frankel, S. Kornfeld, E. Saria, C. Meneghetti, J. Drajesk, D. Fishwild, P. Scannon, and V. Byers. 1991. Phase I trial of H65-RTA immunoconjugate in patients with cutaneous T-cell lymphoma. Blood 78:1173.
34. Amlot, P. L., M. J. Stone, D. Cunningham, J. Fay, J. Newman, R. Collins, R. May, M. McCarthy, J. Richardson, V. Ghetie, O. Ramilo, et al. 1993. A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. Blood 82:2624.
35. Gaudin, M.-C., G. P. Allaway, W. C. Olson, R. Weir, P. J. Maddon, and R. A. Koup. 1998. CD4-IgG2 protects Hu-PBL-SCID mice against challenge by primary HIV-1 isolates. J. Virol. 72:3475.
36. Bonyhadi, M. L., L. Rabin, S. Salimi, D. A. Brown, J. Kosek, J. M. McCune, and H. Kaneshima. 1993. HIV induces thymus depletion in vivo. Nature 363:728.
37. + T cells in human-PBL-SCID mice by noncytopathic HIV isolates. Science 260:689.
38. Wetherall, N. T. 1990. The development of HIV-1 p24 antigenemia in the athymic "nude" mouse. In Animal Models of AIDS. H. Schellekens, and M. C. Horzinek, eds. Elsevier Science Publishers, Amsterdam. p. 291.
39. Sato, A., M. Kodama, K. Abe, S. Miki, M. Nishimura, A. Suyama, M. Ogata, T. Toyoda, H. Sugimoto, and O. Yoshie. 1995. A simple and rapid method for preliminary evaluation of in vivo efficacy of anti-HIV compounds in mice. Antiviral Res. 27:151.
40. Hollingshead, M., J. Roberson, W. Decker, R. Buckheit, C. Elder, L. Malspeis, J. Mayo, and M. Grever. 1995. In vivo drug screening applications of HIV-infected cells cultured within hollow fibers in two physiologic compartments of mice. Antiviral Res. 28:265.
41. Lapenta, C., S. Fais, P. Rizza, M. Spada, M. A. Logozzi, S. Parlato, S. M. Santini, M. Pirillo, F. Belardelli, and E. Proietti. 1997. U937-SCID mouse xenografts: a new model for acute in vivo HIV-1 infection suitable to test antiviral strategies. Antiviral Res. 36:81.
42. Sanhadji, K., L. Grave, J. L. Touraine, P. Leissner, C. Rouzioux, R. Firouzi, L. Kehrli, J. C. Tardy, and M. Mehtali. 2000. Gene transfer of anti-gp41 antibody and CD4 immunoadhesin strongly reduces the HIV-1 load in humanized severe combined immunodeficient mice. AIDS 14:2813.
43. Quenelle, D. C., K. A. Keith, K. E. Dunleavy, B. A. Taylor, B. J. Bowdon, A. D. Brazier, C. J. Mullon, R. E. Harris, and L. B. Allen. 1997. Evaluation of anti-AIDS drugs in conventional mice implanted with a permeable membrane device containing human T cells infected with HIV. Antiviral Res. 35:123.